Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X

Journal of Immunology

Volumn 193, Issue 3, 2014, Pages 1233-1245

  Jung, In Duk ^a   Shin, Sung Jae ^b   Lee, Min Goo ^c   Kang, Tae Heung ^a   Han, Hee Dong ^a   Lee, Seung Jun ^a   Kim, Woo Sik ^b   Kim, Hong Min ^b   Park, Won Sun ^d   Kim, Han Wool ^e,f   Yun, Cheol Heui ^e,f   Lee, Eun Kyung ^g   Wu, T C ^h   Park, Yeong Min ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Kangwon National University   (South Korea)

^e Seoul National University   (South Korea)

^f Seoul National University   (South Korea)

^g Chung Ang University College of Medicine   (South Korea)

^h DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN X; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL POLARITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOCYTOTOXICITY; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS INHIBITION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR GROWTH; TUMOR REGRESSION; UTERINE CERVIX CANCER; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PRIMARY CELL CULTURE; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 84906074259     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400656     Document Type: Article

References (25)

1. Grange, J. M., O. Bottasso, C. A. Stanford, and J. L. Stanford. 2008. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 26: 4984-4990.
2. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306.
3. Bansal, K., S. R. Elluru, Y. Narayana, R. Chaturvedi, S. A. Patil, S. V. Kaveri, J. Bayry, and K. N. Balaji. 2010. PE-PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. J. Immunol. 184: 3495-3504.
4. Pecora, N. D., A. J. Gehring, D. H. Canaday, W. H. Boom, and C. V. Harding. 2006. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J. Immunol. 177: 422-429.
5. Heo, D. R., S. J. Shin, W. S. Kim, K. T. Noh, J. W. Park, K. H. Son, W. S. Park, M. G. Lee, D. Kim, Y. K. Shin, et al. 2011. Mycobacterium tuberculosislpdC, Rv0462, induces dendritic cell maturation and Th1 polarization. Biochem. Biophys. Res. Commun. 411: 642-647.
6. Jung, I. D., S. K. Jeong, C. M. Lee, K. T. Noh, D. R. Heo, Y. K. Shin, C. H. Yun, W. J. Koh, S. Akira, J. Whang, et al. 2011. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res. 71: 2858-2870.
7. Byun, E. H., W. S. Kim, J. S. Kim, I. D. Jung, Y. M. Park, H. J. Kim, S. N. Cho, and S. J. Shin. 2012. Mycobacterium tuberculosis Rv0577, a novel TLR2 agonist, induces maturation of dendritic cells and drives Th1 immune response. FASEB J. 26: 2695-2711.
8. Stewart, G. R., S. M. Newton, K. A. Wilkinson, I. R. Humphreys, H. N. Murphy, B. D. Robertson, R. J. Wilkinson, and D. B. Young. 2005. The stress-responsive chaperone alpha-crystallin 2 is required for pathogenesis of Mycobacterium tuberculosis. Mol. Microbiol. 55: 1127-1137.
9. Roupie, V., M. Romano, L. Zhang, H. Korf, M. Y. Lin, K. L. Franken, T. H. Ottenhoff, M. R. Klein, and K. Huygen. 2007. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNAvaccinated and tuberculosis-infected mice. Infect. Immun. 75: 941-949.
10. Geluk, A., M. Y. Lin, K. E. van Meijgaarden, E. M. Leyten, K. L. Franken, T. H. Ottenhoff, and M. R. Klein. 2007. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect. Immun. 75: 2914-2921.
11. Lin, K. Y., F. G. Guarnieri, K. F. Staveley-O'Carroll, H. I. Levitsky, J. T. August, D. M. Pardoll, and T. C. Wu. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56: 21-26.
12. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
13. Wuyts, A., P. Menten, N. Van Osselaer, and J. Van Damme. 2004. Assays for chemotaxis. Methods Mol. Biol. 249: 153-166.
14. Liu, Y. J. 2001. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106: 259-262.
15. Willimann, K., D. F. Legler, M. Loetscher, R. S. Roos, M. B. Delgado, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1998. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur. J. Immunol. 28: 2025-2034.
16. Schilling, J. D., H. M. Machkovech, L. He, A. Diwan, and J. E. Schaffer. 2013. TLR4 activation under lipotoxic conditions leads to synergistic macrophage cell death through a TRIF-dependent pathway. J. Immunol. 190: 1285-1296.
17. Ojaniemi, M., V. Glumoff, K. Harju, M. Liljeroos, K. Vuori, and M. Hallman. 2003. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 33: 597-605.
18. Koyasu, S. 2003. The role of PI3K in immune cells. Nat. Immunol. 4: 313-319.
19. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
20. Shi, C., L. Chen, Z. Chen, Y. Zhang, Z. Zhou, J. Lu, R. Fu, C. Wang, Z. Fang, and X. Fan. 2010. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine 28: 5237-5244.
21. Peng, S., C. Trimble, L. Wu, D. Pardoll, R. Roden, C. F. Hung, and T. C. Wu. 2007. HLA-DQB1 02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin. Cancer Res. 13: 2479-2487.
22. Okada, N., Y. Masunaga, Y. Okada, H. Mizuguchi, S. Iiyama, N. Mori, A. Sasaki, S. Nakagawa, T. Mayumi, T. Hayakawa, et al. 2003. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther. 10: 1891-1902.
23. Cluff, C. W. 2009. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 667: 111-123.
24. Przetak, M., J. Chow, H. Cheng, J. Rose, L. D. Hawkins, and S. T. Ishizaka. 2003. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine 21: 961-970.
25. Mata-Haro, V., C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell. 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIFbiased agonist of TLR4. Science 316: 1628-1632.